Skip to content
2000
Volume 23, Issue 15
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Cardiotoxicity represents an important acute or chronic adverse event of treatment modalities for childhood cancer. In the last two decades the emergence of novel cancer therapies has aimed to increase unaided or mostly in combination with conventional chemotherapy for the survival rates of pediatric cancer especially for those patients with relapsed and/or refractory disease. The use of emerging targeted therapies in combination with conventional chemotherapy is related to cardiovascular adverse events mostly reported in adults. The aim of our short review was to investigate the cardiotoxic side effects of targeted chemotherapeutic agents as monoclonal antibodies and small molecules in pediatric cancer patients.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520623666230525162147
2023-09-01
2025-03-15
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520623666230525162147
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test